PARP1 and cancer: PARP inhibitors (such as Olaparib, Iniparib, Veliparib, Rucaparib, and Niraparib), a class of small-molecule drugs inhibiting PARP enzymes, can induce synthetic lethality in HRR deficiency cancer cells [10].